This MS drug increases risk of hospitalisation

Published: 27 August 2021

A new study has found that Ocrevus (ocrelizumab) slows disability progression and reduces relapse risk in people with multiple sclerosis (MS) but is also associated with higher hospitalisation risk in older people. 

Most of the hospitalisations were from urinary tract infections, and they were more common in people aged 55 and older than below 55. 

The researchers recommended that a person’s age and disability level should be taken into account when considering treatment with ocrelizumab, and careful monitoring should be given to older patients when using this drug.